Literature review: Risk of adverse fetal effects following short-term second trimester NSAID use

Researchers from Embryotox, the Berlin TIS, have recently published the results of their systematic review focussing on the risk of prenatal ductus arteriosus constriction, oligohydramnios, neonatal renal failure and primary pulmonary hypertension following maternal short-term use of NSAIDs in the second trimester of pregnancy. More information can be found here.

» Read more

Interesting academic highlights article discussing the FDAs pregnancy and lactation labelling rule

Pregnancy labelling of medications is a hotly debated issue in the field of teratology, and several studies have shown the limitations of providing pregnancy safety category ratings for medicines. In this recent academic highlights article, the authors summarise discussions which were held at an April 2017 meeting focussed on pregnancy pharmacogivilance and the FDAs pregnancy and lactation labelling rule. Further […]

» Read more

Additional data made available concerning first trimester dolutegravir use

Researchers from the ENTIS Paris COCHIN Center (Centre Régional de Pharmacovigilance et d’information sur le médicament) at the Assistance Publique-Hopitaux de Paris have published national surveillance data of first-trimester exposure to dolutegravir, raltegravir or elvitegravir in pregnancy, adding to the growing body of evidence available for integrase strand transfer inhibitors. More information can be found here.

» Read more
1 25 26 27 28 29 30